{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T13:54:44Z","timestamp":1778162084880,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,4,11]],"date-time":"2013-04-11T00:00:00Z","timestamp":1365638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s10072-013-1357-1","type":"journal-article","created":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T04:44:31Z","timestamp":1365569071000},"page":"1043-1048","source":"Crossref","is-referenced-by-count":32,"title":["Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence"],"prefix":"10.1007","volume":"34","author":[{"given":"Roberta","family":"Ravenni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"De Grandis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,11]]},"reference":[{"key":"1357_CR1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1517\/14712598.8.6.791","volume":"8","author":"M Maio De","year":"2008","unstructured":"De Maio M (2008) Therapeutic uses of botulinum toxin: from facial palsy to autonomic disorders. Expert Opin Biol Ther 8:791\u2013798","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl 2","key":"1357_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1331.2010.03125.x","volume":"17","author":"A Esquenazi","year":"2010","unstructured":"Esquenazi A, Novak I, Sheean G, Singer BJ, Ward AB (2010) International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments\u2014introduction. Eur J Neurol 17(Suppl 2):1\u20138","journal-title":"Eur J Neurol"},{"key":"1357_CR3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1358\/dot.2010.46.9.1524356","volume":"46","author":"A Brashear","year":"2010","unstructured":"Brashear A (2010) Botulinum toxin type A: exploring new indications. Drugs Today (Barc) 46:671\u2013682","journal-title":"Drugs Today (Barc)"},{"key":"1357_CR4","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1185\/03007990903028203","volume":"25","author":"K Wohlfarth","year":"2009","unstructured":"Wohlfarth K, Sycha T, Ranoux D, Naver H, Caird D (2009) Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin 25:1573\u20131584","journal-title":"Curr Med Res Opin"},{"key":"1357_CR5","first-page":"725","volume":"5","author":"J Park","year":"2011","unstructured":"Park J, Lee MS, Harrison AR (2011) Profile of Xeomin\u00ae (incobotulinumtoxinA) for the treatment of blepharospasm. Clin Ophthalmol 5:725\u2013732","journal-title":"Clin Ophthalmol"},{"key":"1357_CR6","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2147\/OPTH.S24394","volume":"5","author":"A Pickett","year":"2011","unstructured":"Pickett A (2011) Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data. Clin Ophthalmol 5:1287\u20131290","journal-title":"Clin Ophthalmol"},{"key":"1357_CR7","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00003495-200767050-00003","volume":"67","author":"WH Jost","year":"2007","unstructured":"Jost WH, Bl\u00fcmel J, Grafe S (2007) Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 67:669\u2013683","journal-title":"Drugs"},{"key":"1357_CR8","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1080\/09638280701568296","volume":"29","author":"D Dressler","year":"2007","unstructured":"Dressler D, Benecke R (2007) Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 29:1761\u20131768","journal-title":"Disabil Rehabil"},{"issue":"Suppl 1","key":"1357_CR9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1468-1331.2010.03058.x","volume":"17","author":"D Dressler","year":"2010","unstructured":"Dressler D (2010) Botulinum toxin for treatment of dystonia. Eur J Neurol 17(Suppl 1):88\u201396","journal-title":"Eur J Neurol"},{"key":"1357_CR10","first-page":"719","volume":"87","author":"P Hambleton","year":"1994","unstructured":"Hambleton P, Pickett AM (1994) Potency equivalence of botulinum toxin preparations. J R Soc Med 87:719","journal-title":"J R Soc Med"},{"key":"1357_CR11","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/j.1468-1331.2007.01683.x","volume":"14","author":"A Pickett","year":"2007","unstructured":"Pickett A, O\u2019Keeffe R, Panjwani N (2007) The protein load of therapeutic botulinum toxins. Eur J Neurol 14:e11","journal-title":"Eur J Neurol"},{"key":"1357_CR12","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1007\/s00415-008-0031-7","volume":"255","author":"K Wohlfarth","year":"2008","unstructured":"Wohlfarth K, Schwandt I, Wegner F et al (2008) Biological activity of two botulinum toxin type A complexes (Dysport\u00ae and Botox\u00ae) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol 255:1932\u20131939","journal-title":"J Neurol"},{"key":"1357_CR13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.WNF.0000240951.18821.50","volume":"30","author":"K Wohlfarth","year":"2007","unstructured":"Wohlfarth K, Muller C, Sassin I et al (2007) Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin Neuropharmacol 30:86\u201394","journal-title":"Clin Neuropharmacol"},{"key":"1357_CR14","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/jnnp.57.11.1321","volume":"57","author":"S Hesse","year":"1994","unstructured":"Hesse S, L\u00fccke D, Malezic M et al (1994) Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry 57:1321\u20131324","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1357_CR15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/jnnp.61.1.30","volume":"61","author":"BB Bhakta","year":"1996","unstructured":"Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA (1996) Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 61:30\u201335","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1357_CR16","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1212\/WNL.46.5.1306","volume":"46","author":"DM Simpson","year":"1996","unstructured":"Simpson DM, Alexander DN, O\u2019Brien CF et al (1996) Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 46:1306\u20131310","journal-title":"Neurology"},{"key":"1357_CR17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jnnp.69.2.217","volume":"69","author":"BB Bhakta","year":"2000","unstructured":"Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM (2000) Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 69:217\u2013221","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1357_CR18","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1161\/01.STR.31.10.2402","volume":"31","author":"AM Bakheit","year":"2000","unstructured":"Bakheit AM, Thilmann AF, Ward AB et al (2000) A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 31:2402\u20132406","journal-title":"Stroke"},{"key":"1357_CR19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/jnnp.68.6.707","volume":"68","author":"N Hyman","year":"2000","unstructured":"Hyman N, Barnes M, Bhakta B et al (2000) Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 68:707\u2013712","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1357_CR20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000069495","volume":"15","author":"SJ Pittock","year":"2003","unstructured":"Pittock SJ, Moore AP, Hardiman O et al (2003) A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 15:289\u2013300","journal-title":"Cerebrovasc Dis"},{"key":"1357_CR21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000073058","volume":"50","author":"H Woldag","year":"2003","unstructured":"Woldag H, Hummelsheim H (2003) Is the reduction of spasticity by botulinum toxin a beneficial for the recovery of motor function of arm and hand in stroke patients? Eur Neurol 50:165\u2013171","journal-title":"Eur Neurol"},{"key":"1357_CR22","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.apmr.2003.10.015","volume":"85","author":"MK Childers","year":"2004","unstructured":"Childers MK, Brashear A, Jozefczyk P et al (2004) Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 85:1063\u20131069","journal-title":"Arch Phys Med Rehabil"},{"key":"1357_CR23","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1002\/(SICI)1097-4598(1997)6+<208::AID-MUS15>3.0.CO;2-1","volume":"6","author":"MF Brin","year":"1997","unstructured":"Brin MF (1997) Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl 6:S208\u2013S220","journal-title":"Muscle Nerve Suppl"},{"key":"1357_CR24","first-page":"459","volume":"72","author":"D Ranoux","year":"2002","unstructured":"Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M (2002) Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72:459\u2013462","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1357_CR25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.64.1.6","volume":"64","author":"T Odergren","year":"1998","unstructured":"Odergren T, Hjaltason H, Kaakkola S et al (1998) A , randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 64:6\u201312","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1357_CR26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00941758","volume":"235","author":"Z N\u00fcssgens","year":"1997","unstructured":"N\u00fcssgens Z, Roggenk\u00e4mper P (1997) Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 235:197\u2013199","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1357_CR27","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.870120627","volume":"12","author":"C Sampaio","year":"1997","unstructured":"Sampaio C, Ferreira JJ, Sim\u00f5es F et al (1997) DYSPORT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A\u2014Dysport and Botox\u2014assuming a ratio of 4:1. Mov Disord 12:1013\u20131018","journal-title":"Mov Disord"},{"key":"1357_CR28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10072-011-0672-7","volume":"33","author":"AR Bentivoglio","year":"2012","unstructured":"Bentivoglio AR, Ialongo T, Bove F, De Nigris F, Fasano A (2012) Retrospective evaluation of the dose equivalence of Botox\u00ae and Dysport\u00ae in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurol Sci 33:261\u2013267","journal-title":"Neurol Sci"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-013-1357-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-013-1357-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-013-1357-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T08:45:37Z","timestamp":1562921137000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-013-1357-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,11]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["1357"],"URL":"https:\/\/doi.org\/10.1007\/s10072-013-1357-1","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,11]]}}}